Potential advantages of this approach are: (1) that it may avoid some of the pitfalls of targeting upstream signalling events; (2) that it requires no assumptions about the factors that drive inflammation or the signalling pathways actually responsible for the phosphorylation and inactivation of TTP in the RA synovium; (3) that it capitalises on the accumulation of TTP at sites of inflammation,30, 40 a pool of dormant anti-inflammatory effector protein that is ripe for re-activation. Here, ZFP36 is linked to rheumatoid arthritis.